Skip To Content

Study ID: Urigen URG101-105 Bladder Instillation

Title:

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared with the Individual Components Lidocaine and Heparin in Subjects with Bladder Pain Syndrome and Interstitial Cystitis

Location:
Sioux Falls Region
Principal Investigator:
Kevin Benson, MD
Disease:
Stage:
Phase IIA
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.